Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Sep;106(9):1638-45.
doi: 10.1038/ajg.2011.156. Epub 2011 May 10.

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

John E Eaton  1 , Marina G Silveira, Darrell S Pardi, Emmanouil Sinakos, Kris V Kowdley, Velimir A C Luketic, M Edwyn Harrison, Timothy McCashland, Alex S Befeler, Denise Harnois, Roberta Jorgensen, Jan Petz, Keith D Lindor
Affiliations
Randomized Controlled Trial

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

John E Eaton et al. Am J Gastroenterol. 2011 Sep.

Abstract

Objectives: Some studies have suggested that ursodeoxycholic acid (UDCA) may have a chemopreventive effect on the development of colorectal neoplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We examined the effects of high-dose (28-30 mg/kg/day) UDCA on the development of colorectal neoplasia in patients with UC and PSC.

Methods: Patients with UC and PSC enrolled in a prior, multicenter randomized placebo-controlled trial of high-dose UDCA were evaluated for the development of colorectal neoplasia. Patients with UC and PSC who received UDCA were compared with those who received placebo. We reviewed the pathology and colonoscopy reports for the development of low-grade or high-grade dysplasia or colorectal cancer.

Results: Fifty-six subjects were followed for a total of 235 patient years. Baseline characteristics (including duration of PSC and UC, medications, patient age, family history of colorectal cancer, and smoking status) were similar for both the groups. Patients who received high-dose UDCA had a significantly higher risk of developing colorectal neoplasia (dysplasia and cancer) during the study compared with those who received placebo (hazard ratio: 4.44, 95% confidence interval: 1.30-20.10, P=0.02).

Conclusions: Long-term use of high-dose UDCA is associated with an increased risk of colorectal neoplasia in patients with UC and PSC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier estimates of proportion of patients free of colorectal neoplasia according to randomization group. UDCA, ursodeoxycholic acid.
See this image and copyright information in PMC

Comment in

References

    1. Lewis JD, Deren JJ, Lichtenstein GR. Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin N Am. 1999;28:459–77. - PubMed
    1. Silveira MG, Lindor KD. Primary sclerosing cholangitis. Can J Gastroenterol. 2008;22:689–98. - PMC - PubMed
    1. Marchesa P, Lashner BA, Lavery IC, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1997;92:1285–8. - PubMed
    1. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808–14. - PMC - PubMed
    1. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis Ursodoexycholic Acid Study Group. N Engl J Med. 1997;336:691–5. - PubMed

Publication types

MeSH terms